Arthneeti

Torrent Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis

₹4,595.00-0.40% today
Market cap
₹1.75L Cr
P/E
80.51
ROE
27.43%
PEG
3.72
Price to sales
10.04
Debt to equity
0.77
52W high / low
₹5,123 / ₹3,553
Sales growth (5Y)
11.80%
EBITDA margin
33.18%
Net profit margin
15.50%
Promoter holding
60.78%
Sales (last year)
₹17,400 Cr

Guidance scorecard · Q2 FY27 call

What Torrent Pharma.'s management guided
and where it ranks in Pharmaceuticals & Biotechnology

#55of 84 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ2 FY27 call

10–20%
  • Indian pharma market (IPM) growth expected to sustain strong double-digit growth (~10%) at least through next financial year, with potential one-off higher growth this year (12%).
  • US business poised for growth via new product launches, with 4 products filed YTD and 4-5 more expected this fiscal year; growth driven by new products despite pricing pressure.
  • Brazil business expected to grow mid-teens (10-15%) driven by new launches, price, and volume increases despite competitive challenges and regulatory delays.
  • ROW markets (e.g., Philippines, Mexico, Russia, South Africa) growing high single-digit (6-9%).
  • OTC business targeting growth through multiple product extensions and acquisitions; semaglutide (sema) market expanding with stable or gradually increasing pricing.

2 more points from Torrent Pharma.'s call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Torrent Pharma. said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Torrent Pharma plans to increase R&D spend to boost product filings in the US from low single digits to high single digits over the next 2-3 years, aiming to recover lost time due to operational issues.
  • The R&D spend is expected to stabilize around 4% to 4.5% of revenues, seen as a temporary increase for the next couple of years.
  • The company also focuses on product filings and launches in markets like Brazil and ROW, requiring investment in approval processes and commercial execution.
  • Revenue and cost synergies from the JB Chem merger are being realized faster than anticipated, potentially influencing future investment priorities but without expanding the overall capex guidance currently.
Full Q2 FY27 analysis

FundraisingQ2 FY27 call

See what Torrent Pharma. said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

Ask what Torrent Pharma. said on the order book →

Full Q2 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Torrent Pharma. rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹40 Cr—
620–40%Up 2%+₹51,093 Cr44.6

Sign up free to see every company in the sector ranking and track Torrent Pharma..

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Torrent Pharma.

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Torrent Pharma.

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +71.25%71.25%71.25%71.25%68.31%68.31%68.31%68.31%68.31%68.31%68.31%60.78%
FIIs +14.08%14.14%14.22%14.46%16.17%16.31%16.09%15.92%16.13%16.18%15.44%17.22%
DIIs +7.11%7.15%7.17%6.98%8.25%8.25%8.54%9.17%9.05%8.96%9.73%13.37%
Government +0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.00%0.10%0.09%
Public +7.46%7.34%7.25%7.21%7.17%7.02%6.93%6.47%6.41%6.55%6.42%8.54%
No. of Shareholders69,11771,15474,76579,84885,03586,00581,85678,22676,21483,81185,7761,42,140

Financials of Torrent Pharma.

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +2,6602,7322,7452,8592,8892,8092,9593,1783,3023,3034,1974,9214,979
Expenses +1,8351,8631,8621,9551,9501,8951,9952,1462,2192,2152,8413,2573,313
Operating Profit8258698839049399149641,0321,0831,0881,3561,6641,666
OPM %31%32%32%32%32%33%33%32%33%33%32%34%33%
Other Income +26553124-1633-42-37-40-23-83-33-20
Interest91808075645756564845236305300
Depreciation201213203197198199201201204206508593609
Profit before tax559631631656661691665738791814529733737
Tax %31%30%29%30%31%27%25%26%25%22%31%23%28%
Net Profit +386443449457453503498548591635364566534
EPS in Rs11.4113.0913.2713.5013.3814.8614.7116.1917.4618.7610.7616.7214.04

Financials of Torrent Pharma.

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +4,6366,6875,8165,9507,6737,9398,0058,5089,62010,72811,51613,98017,400
Expenses +3,6163,9544,4384,6015,6905,7695,5246,0776,7787,3607,7959,42111,626
Operating Profit1,0202,7331,3771,3491,9832,1702,4802,4312,8423,3683,7214,5585,774
OPM %22%41%24%23%26%27%31%29%30%31%32%33%33%
Other Income +28632223299-30012157-28845146-1-182-159
Interest175184206308504451353255333354252385886
Depreciation1912383074096186546586627078087951,1191,916
Profit before tax9402,3431,0889315621,1871,5261,2261,8472,3522,6732,8722,813
Tax %20%26%14%27%22%14%18%37%33%30%28%26%
Net Profit +7511,7339346784361,0251,2527771,2451,6561,9112,1382,099
EPS in Rs22.1951.2227.5920.0412.8930.2836.9922.9736.7948.9456.4763.9260.28
Dividend Payout %25%34%25%35%66%53%47%105%60%57%57%59%

Financials of Torrent Pharma.

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital8585858585858585169169169169190
Reserves2,4063,4094,2664,5384,6404,7395,7535,8686,0296,6877,4218,21918,183
Borrowings +2,7402,3522,5106,4626,0385,7844,8744,0705,3694,0223,20215,02614,107
Other Liabilities +2,5893,0402,7403,1593,3513,4023,3632,8843,0433,6273,60320,20012,135
Total Liabilities7,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39643,61444,615
Fixed Assets +2,8332,8593,6887,8557,7487,5337,0656,4238,1218,1387,94733,19132,621
CWIP6781,042519647617712889630765361478641404
Investments29878080449235321812261991731569482,160
Other Assets +4,0114,2064,5895,2495,3955,7635,9405,6285,5245,8345,8158,8339,430
Total Assets7,8208,8869,60114,24314,11314,01014,07512,90614,61014,50514,39643,61444,615

Financials of Torrent Pharma.

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +8102,7421,0098941,7981,3932,0051,8032,3683,2662,5853,023
Cash from Investing Activity +-2,113-869-798-4,677-246229-444-196-2,335-160-549-12,630
Cash from Financing Activity +1,212-1,435-1933,417-1,314-1,549-1,651-1,78177-2,780-2,29810,151
Net Cash Flow-9043718-36623873-89-174110327-262544
Free Cash Flow5742,1505231051,1389901,6711,6071,9532,9671,9912,386
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit85%121%101%87%105%77%88%91%97%112%86%84%

Financials of Torrent Pharma.

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1257960776876697074635979
Inventory Days275314318429318362456368298310334338
Days Payable472523356447345345351250224284239254
Cash Conversion Cycle-71-1302159429317418814789154163
Working Capital Days29-128-80-62-52-57-33-277-26
ROCE %27%48%19%13%13%15%17%19%20%23%27%15%

Guidance history

How Torrent Pharma.'s guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →10–20%FlatPlanned——
Q1 FY27 call →10–20%FlatPlanned——
Q3 FY26 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

67out of 100

Momentum score · price trend

67 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+29.1%78%
Last 6 months+8.1%66%
Last 3 months−9.0%47%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Torrent Pharma.: 0.4 × 78 + 0.4 × 66 + 0.2 × 47 = 67.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Torrent Pharma.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt Ltd (Q2 FY27)

    969 crore, up from Rs. Key results statement takeaways from Wockhardt Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • JFL Life (Q2 FY27)

    This represents a year-on-year increase of approximately 96% in revenue for the quarter. Key results statement takeaways from JFL Life Sciences Ltd's Q2 FY27 ea

  • P & G Health Ltd (Q2 FY27)

    Revenue from Operations for the quarter ended September 30, 2026, is ₹38,249 lakhs (Page 4). Key results statement takeaways from Procter & Gamble Health Ltd's

  • Akums Drugs (Q2 FY27)

    Q2 FY27 revenue reported at ₹1,342 crore, up 31.9% YoY from ₹1,018 crore in Q2 FY26 (Page 12, 10). Key investor presentation takeaways from Akums Drugs & Pharma

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Laurus Labs